NewLink Prices IPO to Raise Up to $50M for Cancer Vaccine
BioWorld Today Contributing Writer
After nearly a year of anticipation, NewLink Genetics Corp., of Ames, Iowa, priced its initial public offering of 6.2 million shares at $7 per share, with an underwriters' option of 930,000 additional shares. The offering could raise $49.9 million for the biotech, which specializes in cancer immunotherapeutics.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST